Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration

Retina

Volumn 26, Issue 9, 2006, Pages 994-998

  Yoganathan, Pradeepa ^a   Deramo, Vincent A ^a,b   Lai, James C ^a,b   Tibrewala, Rajen K ^c   Fastenberg, David M ^a,b  

^a North Shore Long Island Jewish Health System ^*  (United States)

^b Long Island Vitreoretinal Consultants   (United States)

^c NEW YORK INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Age related macular degeneration; Avastin; Bevacizumab; Choroidal neovascularization; Vascular endothelial growth factor

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AGING; ARTICLE; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM; TREATMENT OUTCOME; VISION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BLOOD PRESSURE; CHOROIDAL NEOVASCULARIZATION; EXUDATES AND TRANSUDATES; FEMALE; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR DEGENERATION; MALE; MIDDLE AGED; RETINA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 33845750072     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iae.0000244380.34082.67     Document Type: Article

References (12)

1. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-1642.
2. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic factors in age-related maculopathy. Br J Ophthalmol 1997;81:154-162.
3. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
4. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-346.
5. Gragoudas ES, Adamis AP, Cunnighman ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
6. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2006;113:633-642.
7. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature 2004;3:391-400.
8. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-1047.
9. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
10. Early Treatment Diabetic Retinopathy Study Research Group. Early treatment diabetic retinopathy study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 1991;98:741-756.
11. Rosiak J, Sadowski L. Hypertension associated with bevacizumab. Clin J Oncol Nurs 2005;9:407-411.
12. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.